Suvankar Pal

Suvankar Pal

Auto-generated profile, based on publicly available information

Suvankar Pal

Anne Rowling Regenerative Neurology Clinic, University of Edinburgh, Edinburgh, UK

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 May 2021 in Nature Reviews Neurology
Verified
Journal Article
Open access
PDF file
NWNeil Watson
Neil Watson
JBJean-Philippe Brandel
Jean-Philippe Brandel
AGAlison Green
Alison Green
PHPeter Hermann
Peter Hermann
ALAnna Ladogana
Anna Ladogana
SPSuvankar Pal
Suvankar Pal
Creutzfeldt–Jakob disease (CJD) is a rapidly progressive, fatal and transmissible neurodegenerative disease associated with the accumulation of misfolded prion protein in the CNS. International CJD surveillance programmes have been active since the emergence, in the mid-1990s, of variant CJD (vCJD), a disease linked to bovine spongiform encephalopathy. Control measures have now successfully contained bovine spongiform encephalopathy and the incidence of vCJD has declined, leading to questions about the requirement for ongoing surveillance. However, several lines of evidence have raised concerns that further cases of vCJD could emerge as a result of prolonged incubation and/or secondary transmission. Emerging evidence from peripheral tissue distribution studies employing high-sensitivity assays suggests that all forms of human prion disease carry a theoretical risk of iatrogenic transmission. Finally, emerging diseases, such as chronic wasting disease and camel prion disease, pose further risks to public health. In this Review, we provide an up-to-date overview of the transmission of prion diseases in human populations and argue that CJD surveillance remains vital both from a public health perspective and to support essential research into disease pathophysiology, enhanced diagnostic tests and much-needed treatments.

28 June 2018 in BMC Neurology
Verified
Journal Article
Open access
PDF file
VMVivek Majumder
Vivek Majumder
JGJenna M. Gregory
Jenna M. Gregory
MBMarcelo Barria
Marcelo Barria
AGAlison Green
Alison Green
SPSuvankar Pal
Suvankar Pal
Frontotemporal dementia (FTD) and Amyotrophic Lateral Sclerosis (ALS) are incurable, progressive and fatal neurodegenerative diseases with patients variably affected clinically by motor, behavior, and cognitive deficits. The accumulation of an RNA-binding protein, TDP-43, is the most significant pathological finding in approximately 95% of ALS cases and 50% of FTD cases, and discovery of this common pathological signature, together with an increasing understanding of the shared genetic basis of these disorders, has led to FTD and ALS being considered as part of a single disease continuum. Given the widespread aggregation and accumulation of TDP-43 in FTD-ALS spectrum disorder, TDP-43 may have potential as a biomarker in these diseases. We therefore conducted a systematic review and meta-analysis to evaluate the diagnostic utility of TDP-43 detected in the cerebrospinal fluid (CSF) of patients with FTD-ALS spectrum disorder. From seven studies, our results demonstrate that patients with ALS have a statistically significantly higher level of TDP-43 in CSF (effect size 0.64, 95% CI: 0.1–1.19, p = 0.02). These data suggest promise for the use of CSF TDP-43 as a biomarker for ALS.

31 January 2022 in JAMA Network Open
Verified
Journal Article
Open access
PDF file
NWNeil Watson
Neil Watson
PHPeter Hermann
Peter Hermann
ALAnna Ladogana
Anna Ladogana
ADAngeline Denouel
Angeline Denouel
SBSimone Baiardi
Simone Baiardi
SPSuvankar Pal
Suvankar Pal
Sporadic Creutzfeldt-Jakob disease (sCJD) is a rapidly progressive, universally lethal and transmissible prion disease.1 Incidence has been increasing across multiple nations for several decades.1-3 Clinical features include rapidly progressive cognitive decline with associated motor features and myoclonus progressing to akinetic mutism.4 Median survival is 5 months.5 International surveillance systems monitor epidemiological trends and address attendant public health concerns.1

31 July 2013 in Journal of Neural Transmission
Verified
Journal Article
Closed access
PDF file
CMChristina Micanovic
Christina Micanovic
SPSuvankar Pal
Suvankar Pal

6 August 2013 in European Archives of Psychiatry and Clinical Neuroscience
Verified
Journal Article
Closed access
PDF file
JYJing Ming Yeo
Jing Ming Yeo
XLXuxin Lim
Xuxin Lim
ZKZubair Khan
Zubair Khan
SPSuvankar Pal
Suvankar Pal

1 March 2015 in Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring
Verified
Journal Article
Open access
JYJing Ming Yeo
Jing Ming Yeo
BWBriony Waddell
Briony Waddell
ZKZubair Khan
Zubair Khan
SPSuvankar Pal
Suvankar Pal
Background: Amyloid imaging using fluorine 18–labeled tracers florbetapir, florbetaben, and flutemetamol has recently been reported in Alzheimer's disease (AD).Methods: We systematically searched MEDLINE and EMBASE for relevant studies published from January 1980 to March 2014. Studies comparing imaging findings in AD and normal controls (NCs) were pooled in a meta‐analysis, calculating pooled weighted sensitivity, specificity, and diagnostic odds ratio (OR) using the DerSimonian‐Laird random‐effects model.Results: Nineteen studies, investigating 682 patients with AD, met inclusion criteria. Meta‐analysis demonstrated a sensitivity of 89.6%, a specificity of 87.2%, and an OR of 91.7 for florbetapir in differentiating AD patients from NCs, and a sensitivity of 89.3%, a specificity of 87.6%, and a diagnostic OR of 69.9 for florbetaben. There were insufficient data to complete analyses for flutemetamol.Conclusions: Results suggest favorable sensitivity and specificity of amyloid imaging with fluorine 18–labeled tracers in AD. Prospective studies are required to determine optimal imaging analysis methods and resolve outstanding clinical uncertainties.